Tumor heterogeneity, especially in the metastatic phase, is influenced by various factors including histological subtypes (such as adenocarcinoma and squamous cell lung cancer) and genetic mutations (such as those in EGFR, BRAF, KRAS, and ALK translocations). This evidence concerns the gene EGFR and neoplasm.